Siric > Non classé @en > Rencontre thématique : Oncology Horizon 2030 – 12 mai à Toulouse

Rencontre thématique : Oncology Horizon 2030 – 12 mai à Toulouse

oncology horizon 2030

Eurobiomed Cluster invites you on May 12, 2022 to its next thematic meeting dedicated to oncology, in partnership with the Occitanie Region, Ad’occ and Toulouse Métropole. The event, sponsored by Pierre Fabre, will take place at the Hôtel de Région in Toulouse.

This day will address the prospects in oncology by 2030. More specifically, it will focus on innovations in precision medicine and heterogeneity of tumors, themes opening up prospects for more personalized medicine for better patient care.

PROGRAM
8:45 : Welcome9:15 : Opening by Eurobiomed, Région Occitanie & Toulouse Métropole9:40 : Clinical implications of tumor heterogeneity

Pr Jean-Pierre DELORD – Director of Institut Universitaire du Cancer – Toulouse Oncopole

10:05 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 1st session

  • Multimodal single cell omics : a technological revolution for fundamental and clinical oncologyJean-Jacques FOURNIE, Centre de Recherche en Cancérologie de Toulouse
  • Computational biology approaches to characterise and model the tumour microenvironmentVera PANCALDI, Centre de Recherche en Cancérologie de Toulouse
  • Development of NIK modulators for cancer treatmentArnaud FOUSSAT, CEO Yukin Therapeutics

11:15 : Coffee Break

11:35 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 2nd session

  • Protein glycosylation and cellular interfaces in cancer biologyFrédéric BARD, Centre de Recherche en Cancérologie de Marseille
  • Harnessing innate immunity in cancer therapyAriane MOREL, Director R&D – Pharmacology Department, Innate Pharma

12:25 : Lunch

14:00 : Role of stromal heterogeneity in immunosuppression and resistance to immunotherapy in cancer

Fatima MECHTA-GRIGORIOU, Institut Curie (by videoconference)

14:25 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 3rd session

  • What is neutrophil homeostasis telling us on immune checkpoint blockade in NSCLC?Julien FAGET, Institut de Recherche en Cancérologie de Montpellier
  • High endothelial venules (HEVs): specialized blood vessels for lymphocyte entry into tumors during cancer immunotherapyJean-Philippe GIRARD, Institut de Pharmacologie et de Biologie Structurale de Toulouse
  • Diag2tec’s tools and models to study the response to new therapeutic agents in hematological malignanciesDiag2tec, speaker to be confirmed
  • Microbiomes contribute to tumor microenvironment, progression and treatment responsivenessCéline RIBIERE, Microbiome Scientist Vaiomer

15:55 : Oncology at Pierre Fabre – A strategic perspective

Francesco HOFMANN Medical Care R&D Director

16:20 : Closing by Eurobiomed

16:25 : End of the event

Registrations

FREE BUT MANDATORY REGISTRATON BEFORE May 9, 2022

REGISTER ON LINE 

Information : Leïla TOUIHRI, Eurobiomed

leila.touihri@eurobiomed.org